Theravance Inc news

   Watch this stock
Showing stories 1 - 10 of about 95   

Articles published

THRX 17.92 +0.46 (2.63%)
price chart
Active Watch List: Theravance Inc. (NASDAQ:THRX), Petroleo Brasileiro ...
Theravance Inc. (NASDAQ:THRX) belongs to Healthcare sector. Its weekly performance is -1.16%. On last trading day company shares ended up $17.46.
Theravance, Inc. Announces May 15 Record Date and June 2 Share Issue Date ...
SOUTH SAN FRANCISCO, CA, May 06, 2014 (Marketwired via COMTEX) -- Theravance, Inc. THRX, +2.19% (the "Company" or "Theravance") has announced the record date of May 15, 2014 for the Company's strategic separation into two independent, ...
Theravance, Inc. (THRX) Announces Record Date for Separation Into Two ...  StreetInsider.com (subscription)
Split Update Overshadows Wider Q1 Loss at Theravance - Analyst Blog  NASDAQ
Related articles »  
Volatile Theravance Inc. Offers Attractive Total Returns Potential (THRX)
Theravance, Inc. is a royalty management company. The South San Francisco, California-headquartered company is primarily focused on maximizing the potential value of the respiratory assets partnered with United Kingdom-based pharmaceutical giant ...
Theravance Inc. (NASDAQ:THRX) declared a quarterly dividend
Theravance Inc. (NASDAQ:THRX) declared a quarterly dividend on February 24th, Analyst Ratings News reports. Investors of record on Thursday, March 12th will be paid a dividend of 0.25 per share on Tuesday, March 31st.
Theravance, Inc. and Theravance Biopharma, Inc. Announce Completion of ...
Theravance, Inc., A Royalty Management Company, is focused on maximizing the potential value of the respiratory assets partnered with GlaxoSmithKline plc including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(TM) ELLIPTA(R) and providing capital ...
Why Theravance Inc.'s 22% Drop Isn't What It Appears
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
Related articles »  
Pitney Bowes Inc. (PBI) and Theravance Inc (THRX)'s Stakes Further Rise In ...
In two recently amended filings David Cohen and Harold Levy's Iridian Asset Management has disclosed further increasing its passive stakes in Theravance Inc (NASDAQ:THRX) to 12.40 million shares from 10.8 million shares held earlier, and in Pitney ...
Why Tiffany & Co. (TIF), AK Steel Holding Corporation (AKS) and Theravance Inc ...
tiffany1 Why Tiffany & Co. (TIF), AK Steel Holding Corporation (AKS Not every ticker was jumping for joy on Friday, however. Tiffany & Co.
Traders Stocks Alert: AK Steel Holding Corporation (NYSE:AKS), Theravance ...  Market News Call
Theravance -10.4% following FDA's Breo Ellipta ruling (THRX)
Theravance (NASDAQ:THRX) has fallen to $16.11 in AH trading after the FDA advisory committee backed the use of GlaxoSmithKline's Breo Ellipta inhaler for treating asthma in adults, but not in adolescents.
GSK and Theravance Announce Outcome of US FDA Advisory Committee on ...  Marketwired (press release)
Theravance/Glaxo's Breo Ellipta Gets Mixed FDA Panel View  Zacks.com
GSK And Theravance: Implications Of The Advisory Panel Decision
The drug is co-developed by GSK (NYSE:GSK) and Theravance (NASDAQ:THRX) and is already approved for asthma in Japan. In Europe it is approved for asthma in patients above age 12 (and for COPD, just like in the U.S.